MPS Limited shareholders have overwhelmingly approved two special resolutions through postal ballot voting, demonstrating strong support for key corporate governance and operational decisions. The voting process concluded on 06 February 2026, with results announced on 09 February 2026 through an official scrutinizer report.

Voting Results Overview

The postal ballot process covered two critical resolutions, both of which received requisite majority approval from shareholders. Out of 30,479 total shareholders holding 1,71,05,816 shares, 103 shareholders participated in the remote e-voting process conducted by Central Depository Services (India) Limited (CDSL).

Director Re-appointment Approved

Shareholders approved the re-appointment of Mr. Suhas Khullar (DIN: 07593659) as Independent Non-Executive Director with overwhelming support. The resolution received 12,987,750 votes in favour, representing 99.95% of total valid votes cast, while only 5,920 votes were cast against, representing 0.05% of the total.

Mr. Khullar will serve a second term of five consecutive years from 01 January 2026 to 31 December 2030. His initial appointment as Independent Director was for a two-year term starting 01 January 2024, which expired on 31 December 2025.

Registered Office Relocation Sanctioned

The second resolution regarding the shifting of the company's registered office received even stronger support, with 12,993,559 votes in favour representing 99.999% of valid votes cast. Only 110 votes were recorded against the resolution, representing 0.001% of the total.

The registered office will be relocated from RR Towers IV, Super A, 16/17, Thiru-Vi-Ka Industrial Estate, Guindy, Chennai, Tamil Nadu – 600032 to Block-B6, 3rd Floor, Gateway Office Parks, No. 16, G.S.T Road, Perungalathur, Chennai, Tambaram, Kanchipuram, Tamil Nadu-600063, effective from 01 April 2026.

Official Documentation and Compliance

The company has submitted the official scrutinizer report to both NSE (Symbol: MPSLTD) and BSE (Scrip Code: 532440) under Regulation 44(3) of SEBI Listing Regulations. R. Sridharan & Associates, Company Secretaries, served as the appointed scrutinizer for the postal ballot process.

The voting process was conducted through remote e-voting from 08 January 2026 (9:00 a.m. IST) to 06 February 2026 (5:00 p.m. IST). The voting results and scrutinizer's report have been made available on the company's website at www.mpslimited.com and CDSL's website at www.cdslindia.com , ensuring transparency and compliance with regulatory requirements.

MPS Limited has announced a strategic investment of $16.5 million in Unbound Medicine and has now scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA. The company has formally notified stock exchanges about the conference call scheduled for February 18, 2026, marking a significant development in its North American healthcare technology expansion.

Conference Call Details

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, MPS Limited has scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA by MPS North America LLC, a wholly-owned subsidiary of the company.

Investment Structure and Strategic Approach

The $16.5 million investment combines both debt and equity components, providing MPS with a balanced financial structure for this strategic partnership. This mixed financing approach allows for optimal capital deployment while maintaining strategic flexibility in the partnership with Unbound Medicine.

Management Participation

Mr. Rahul Arora, Chairman and CEO, along with the senior management team of MPS Limited will be present to address the conference call. The company has provided multiple dial-in numbers including universal dial-in numbers, India national toll-free numbers, and international toll-free numbers for various countries including USA, UK, Singapore, Hong Kong, Australia, China, and Germany.

Strategic Implications

This acquisition represents MPS Limited's commitment to strengthening its foothold in the North American healthcare technology landscape through its subsidiary MPS North America LLC. The mixed debt-equity investment structure provides both companies with the financial flexibility needed to pursue aggressive growth strategies while maintaining operational independence. The partnership is expected to enhance both companies' competitive positioning in the rapidly evolving healthcare technology market.